{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-063806","form_type":"8-K","ticker":"NKTR","cik":"0000906709","company_name":"NEKTAR THERAPEUTICS","filed_at":"2023-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:36.975981+00:00","generated_at":"2026-06-12T05:26:05.009763+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Nektar corrects REZPEG Phase 1b data; atopic dermatitis EASI-75 rate now 41% vs 29% reported by Lilly","bullets":["Highest REZPEG dose (24 µg/kg) in atopic dermatitis achieved 83% mean EASI improvement (p=0.002 vs placebo).","EASI-75 response rate corrected from previously reported 29% to 41% (NRI) and 58% as observed.","Psoriasis data also corrected: PASI-50 rate rose to 32% (NRI) and PASI-75 to 21% (NRI); p-values remained non-significant.","Errors discovered after Lilly returned rights; independent statistical firm reanalyzed raw data.","Nektar plans to start Phase 2b study in moderate-to-severe atopic dermatitis in October 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-063806","json":"https://secwatch.observer/filing/0001213900-23-063806.json","markdown":"https://secwatch.observer/filing/0001213900-23-063806.md","text":"https://secwatch.observer/filing/0001213900-23-063806.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/906709/000121390023063806/0001213900-23-063806-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/906709/000121390023063806/ea182964-8k_nektar.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T05:26:05.009763+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}